# Barricaid

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/barricaid

- Industry: Medical Devices & Equipment
- Headquarters: Woburn, US
- Website: www.barricaid.com
- Total disclosed funding: $138M
- Latest round: Series H (Mar 21, 2017)
- Investors on record: 9

## About

Intrinsic Therapeutics, Inc. is a US-based company focused on developing innovative medical solutions for lumbar herniated disc treatment, featuring the Barricaid implant designed to enhance surgical outcomes and minimize complications.Intrinsic Therapeutics, Inc. specializes in medical devices for lumbar herniated disc treatment. Founded in 2000 in Woburn, US, the company has engaged in 15 deals and has raised a total of USD 5.91 mn, with the latest funding round being a Series A of USD 5.91 mn. The current company valuation stands at USD 10.93 mn. The company was founded by Jacob Einhorn.Intrinsic Therapeutics specializes in innovative solutions for lumbar herniated disc treatment, with its flagship product being the Barricaid bone-anchored implant. This device is the first of its kind to have clinical validation demonstrating its efficacy in reducing reherniation and the need for reoperation among patients with significant annular defects. Designed for individuals at high risk of complications post-discectomy, Barricaid optimizes surgical outcomes and alleviates associated debilitating pain. The company targets a diverse client base, including patients undergoing spinal surgery and the surgeons who perform these procedures, primarily within the United States. Notably, Barricaid is FDA-approved for sale in the U.S. market, though it is not available in Europe, positioning it within a specific geographic scope that highlights its focus on American healthcare providers and patients.Intrinsic Therapeutics generates revenue primarily through the sale of its Barricaid implant to healthcare facilities and surgical centers specializing in spinal procedures. The transaction model typically involves direct sales to hospitals and outpatient surgery centers, where the implant is utilized during discectomy surgeries. Pricing structures for the Barricaid device are determined by agreements with healthcare providers, ensuring competitive rates for hospitals while maintaining profitability for the company. Given the focus on clinical evidence and patient outcomes, the sales process is supported by educational initiatives for surgeons, enhancing product adoption and facilitating recurring purchases as new patients undergo treatment. The company's revenue is directly tied to the volume of surgeries performed utilizing the Barricaid implant, indicating a business model that aligns closely with surgical practices and patient care needs.Intrinsic Therapeutics aims to expand its market presence by introducing new products designed for lumbar disc treatment. The company will utilize its recent Series A funding to support these innovations and enhance its marketing initiatives. Plans are also in place to explore opportunities for expansion in new geographic regions, focusing on increasing market share within the United States, with a potential eye towards future international markets, although specific timelines for these expansions have yet to be disclosed. Additionally, the firm recently saw New Leaf Venture Partners realize its investment, indicating strategic shifts towards growth and sustainability.

## Funding rounds

- Series H, Mar 21, 2017, $11M — New Enterprise Associates, Greenspring Associates, Quadrille Capital, Delos Capital Partners
- Series H, Dec 1, 2016, $18M — Greenspring Associates, New Enterprise Capital, Quadrille Capital, Delos Capital Partners
- Series G, Aug 22, 2014, $17M — Spray Venture Partners, New Leaf Venture Partners, New Enterprise Capital
- Series F, Oct 26, 2012, $12M — New Enterprise Associates, Spray Venture Partners, New Leaf Venture Partners
- Series E, Jun 17, 2010, $9.8M — New Enterprise Associates, Spray Venture Partners, Sprout Group
- Series E, Feb 12, 2010, $18M — New Enterprise Associates, Spray Venture Partners, Quilvest Capital Partners, New Leaf Venture Partners
- Series D, Jul 10, 2007, $21M — New Enterprise Associates, Spray Venture Partners, Sprout Group, Quilvest Capital Partners, New Leaf Venture Partners
- Series C, Dec 27, 2002, $25M — New Enterprise Associates, Spray Venture Partners, Sprout Group
- Series B, Jan 3, 2001, $7.5M — New Enterprise Associates, Spray Venture Partners

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B, Series C, Series D, Series E, Series F, Series H
- Spray Venture Partners (https://capitalatlas.ai/funds/spray-venture-partners) — Series B, Series C, Series D, Series E, Series F, Series G
- Sprout Group (https://capitalatlas.ai/funds/sprout-group) — Series C, Series D, Series E
- Quilvest Capital Partners (https://capitalatlas.ai/funds/quilvest-capital-partners) — Series D, Series E
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series D, Series E, Series F, Series G
- New Enterprise Capital (https://capitalatlas.ai/funds/new-enterprise-capital) — Series G, Series H
- Greenspring Associates (https://capitalatlas.ai/funds/greenspring-associates) — Series H
- Quadrille Capital (https://capitalatlas.ai/funds/quadrille-capital) — Series H
- Delos Capital Partners (https://capitalatlas.ai/funds/delos-capital-partners) — Series H